Founder Letter

If you’ve made it this far, thank you.

Choosing to invest in an early-stage company is a big decision, and I don’t take that lightly. You’re not investing in revenue or a finished product. You’re investing in people, in an idea, and in a belief that the future can be better than the present. That deserves honesty from me.

So instead of starting with market sizes and projections, I’d rather tell you why I started AnywhereDx in the first place.

I never set out to build a diagnostics company.

I was simply a mother raising four children, and like every parent, sickness never seemed to happen at a convenient time. A sore throat could derail an entire day. First came the phone calls trying to get into the pediatrician. If they couldn’t see us, it was urgent care. Then pulling a child out of school, missing work, sitting in a waiting room with other sick families, paying what could easily become a $250 visit, and waiting for someone to answer what felt like such a simple question.

Is it strep?

I remember asking myself over and over again, why does it have to be this hard? We can deposit checks from our phones, have groceries delivered to our front door, and talk to someone on the other side of the world instantly. Yet when it comes to something as common as strep throat, why do I still have to spend half my day driving somewhere just to find out if my child needs antibiotics?

The irony is that strep isn’t really the problem.

The problem is the journey.

For decades, diagnosing common infections has required families to fit their lives around the healthcare system instead of the healthcare system fitting around families.

I knew I couldn’t have been the only one thinking this. Every year, roughly 60 million strep tests are performed. Millions of parents are living this exact same story, and while everyone accepted it as normal, I couldn’t help but wonder if “normal” was simply outdated.

Then something remarkable happened. COVID forced healthcare to rethink what was possible.

Before the pandemic, most physicians would never have trusted an at-home diagnostic test enough to make treatment decisions. That changed almost overnight, and one of the people responsible for changing that conversation was my now co-founder, Dr. Michael Mina. His work helped demonstrate that high-quality testing didn’t have to happen inside a doctor’s office to be clinically meaningful.

For me, that was the moment everything clicked.

The question was no longer, “Would this ever be possible?”

It became, “Why aren’t we building it?”

Today, that’s exactly what we’re doing.

We’re building a platform that allows families to move from symptoms to diagnosis to treatment without spending half a day navigating the healthcare system. Imagine your child wakes up with a sore throat. You perform a molecular-quality test at home. If the result is positive, you’re connected with a physician licensed in your state who can review your results and, when appropriate, prescribe treatment through telehealth. Our goal is simple: give families answers quickly, safely, and at a price that’s less than what many people pay just to walk through the doors of an urgent care.

People often ask why we started with strep, and the answer is because it’s the perfect place to begin. It is common, time-sensitive, requires a confirmed diagnosis before treatment, and yet the patient experience has barely changed in decades. But I don’t view this as we’re building a strep company. I view it as building a new model for diagnosing infectious disease at home. Strep is simply where the journey begins.

Another question I hear all the time is, “If this opportunity is so compelling, why are you raising on WeFunder?”

It’s a fair question, and I think you deserve a real answer.

The truth is that we’re still early. We have important clinical, technical, and regulatory milestones ahead of us. Those milestones reduce risk, and institutional investors know it. Many venture firms prefer to invest after those milestones have been achieved, not before. That’s why we’re aggressively pursuing non-dilutive funding and grants today. Every milestone we reach before a priced round makes the company stronger and creates value without diluting our shareholders.

But that’s only part of the answer.

The other reason is much more personal.

I’ve spent enough time around startups to know that some of the best investment opportunities are often reserved for people who can write six- or seven-figure checks. That never felt right to me. The parents living this problem, the physicians caring for these patients, the teachers watching children miss school, the everyday families who understand exactly why this matters—they almost never get the chance to invest alongside professional investors.

I wanted to change that.

That’s why we’re here.

If you invest $100, you become part of this story alongside someone investing $100,000. I think that’s pretty special.

I also want to be transparent about something else. This is an early-stage company. There are risks. We have a tremendous amount of work ahead of us, and I can’t promise you how this story ends. No founder honestly can. What I can promise is that every decision we make is guided by the same question that started this company in the first place:

How do we make healthcare work better for families?

If we answer that question well, I believe the business will follow.

If you’ve decided to join us, thank you. It means more to me than you know. I hope that years from now, when parents can diagnose and begin treating common infectious diseases from the comfort of their homes, you’ll be able to say you were one of the people who believed it could be done before the rest of the world caught up.

Welcome to AnywhereDx. I’m grateful you’re here.

Nathalya

For Those Who Want the Facts

The rest of this page is meant to answer the questions I would expect from any thoughtful investor. I believe both stories and data matter, so here’s a snapshot of where we are today.

Have additional questions? Ask them publicly or send me a message here on WeFunder. I’ll gladly answer them (and probably add them here too)

What problem are you solving?

1. Approximately 60 million strep tests are performed annually in the United States.
2. Families often spend $150–250+ and lose hours of work or school simply to obtain a diagnosis.
3. Our goal is to reduce that journey from hours to under one hour, entirely from home for the cost of less than a copay.

What are you building?

An FDA-regulated molecular diagnostic platform that combines:

1. At-home molecular testing
2. Telehealth integration
3. Prescription fulfillment (when clinically appropriate)

Beginning with Strep A, with a platform designed to expand into additional infectious diseases.

Why start with Strep?

Strep checks every box for an initial indication:

1. High-volume disease
2. Time-sensitive treatment
3. Diagnosis required before antibiotics
4. Minimal innovation in patient workflow over the last two decades

What have we accomplished so far?

1. Regulation CF campaign approved by the SEC
2. Founding team assembled, including Dr. Michael Mina and Dr. Nikhil Gopalkrishnan
3. Non-dilutive grant funding secured
4. Continued advancement toward clinical and regulatory milestones
5. Almost 100 early investors validating consumer demand

How are you funding the company?

Our strategy is intentional.

We are combining:

1. Non-dilutive grant funding
2. Community investment through WeFunder
3. Institutional capital at the appropriate stage

Our goal is to reach meaningful technical and clinical milestones before raising a larger priced institutional round.

Why WeFunder instead of traditional venture capital?

Because these opportunities are normally unavailable to everyday investors.

Institutional fundraising remains part of our long-term strategy, but I wanted parents, physicians, scientists, and people who believe in this mission to have the opportunity to invest alongside future institutional investors—not after them.

What comes next?

Over the next 18–24 months our priorities are straightforward:

1. Clinical validation
2. FDA regulatory progress
3. Expansion of non-dilutive funding
4. Platform development
5. Preparation for institutional financing

Every milestone is designed to reduce risk and increase the value of the company before our next financing event.

If this mission resonates with you, I'd be honored to have you join us. Invest today.

You're helping us build a future where families can get answers faster, begin treatment sooner, and spend less time navigating a healthcare system that wasn't designed with them in mind.

I hope you'll become part of the AnywhereDx story.